Company news
Sensorion Sas (EURONEXT:ALSEN) news
Sensorion Sas news releases on 6ix. Latest, Sep 18, 2026: Sensorion Announces Connection Details for its SENS-601 Program Day on September 22, 2026
Press releases & updates
Sensorion Announces Connection Details for its SENS-601 Program Day on September 22, 2026
September 18, 2026
Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering
September 16, 2026
Sensorion Announces the Completion of Its Reverse Share Split
September 15, 2026
Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
September 3, 2026
Sensorion Announces a Reverse Share Split of its Shares
July 29, 2026
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
June 10, 2026
Sensorion Appoints Fred Chereau as Chief Executive Officer
May 18, 2026
Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 5, 2026
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 11, 2026
April 21, 2026
Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-in-Human Clinical Development
March 23, 2026
Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
March 18, 2026
Sensorion Announces Leadership Changes
February 17, 2026
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting
February 6, 2026
Sensorion Announces EUR60 Million Financing with a EUR20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists to Advance Genetic Medicine Pipeline
January 29, 2026
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
January 28, 2026
Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 19, 2025
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
December 8, 2025
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
September 17, 2025
Sensorion Announces its Participation in the 60th Annual Inner Ear Biology Workshop
September 4, 2025
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
August 15, 2025
Sensorion Announces Its Participation In Upcoming Investor Conferences
July 31, 2025
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
July 29, 2025
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
July 1, 2025
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
May 13, 2025
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
May 6, 2025
Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting
April 25, 2025